Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab versus investigator's choice chemotherapy in recurrent or metastatic cervical carcinoma
jRCT2080223984Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jul 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of cemiplimab in Cervical Cancer (CC) (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Overall survival. Started Jul 2018; status: completed.
02
Drugs
cemiplimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on jRCT2080223984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223984.